Fate Therapeutics (FATE) Tops Q2 EPS by 2c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.02 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.02 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• S&P Global releases recast financials after Mobility spin-off
• Deutsche sees attractive entry point in Consumer Staples, Real Estate